China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
REDWOOD CITY, Calif., March 02, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that Coherus BioSciences’ Vice President of Government Affairs, Juliana Reed testified in support of the reauthorization of the Biosimilar User Fee Program for FY2018 –FY2022 (BsUFA II) on behalf of the Biosimilars Forum at the House Energy and Commerce Committee hearing on FDA’s generic drug and biosimilar user fee programs.
Ms. Reed spoke in support of the reauthorization of BsUFA II, highlighting its importance to not only the biosimilars industry, but also to patients and the healthcare system as a whole.
Denny Lanfear, President and Chief Executive Officer of Coherus BioSciences, stated: “I would like to communicate our unequivocal support of BsUFA II and emphasize how important adequate funding and support of the FDA biosimilars program is to the success of our industry and the future increased patient access and cost-savings these medicines will bring. On behalf of Coherus BioSciences, I strongly encourage Congress to demonstrate its support of the FDA and biosimilars by reauthorizing BsUFA II in a timely manner.”
You can read Ms. Reed’s full testimony by following the link below:
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O'Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
